Objective. Endoplasmic reticulum aminopeptidase 1 (ERAP-1) and ERAP-2, encoded on chromosome 5q15, trim endogenous peptides for HLA-mediated presentation to the immune system. Polymorphisms in ERAP1 and/or ERAP2 are strongly associated with several immunemediated diseases with specific HLA backgrounds, implicating altered peptide handling and presentation as prerequisites for autoreactivity against an arthritogenic peptide. Given the thorough characterization of disease risk-associated polymorphisms that alter ERAP activity, this study aimed instead to interrogate the expression effect of chromosome 5q15 polymorphisms to determine their effect on ERAP isoform and protein expression.
Objective. Endoplasmic reticulum aminopeptidase 1 (ERAP-1) and ERAP-2, encoded on chromosome 5q15, trim endogenous peptides for HLA-mediated presentation to the immune system. Polymorphisms in ERAP1 and/or ERAP2 are strongly associated with several immunemediated diseases with specific HLA backgrounds, implicating altered peptide handling and presentation as prerequisites for autoreactivity against an arthritogenic peptide. Given the thorough characterization of disease risk-associated polymorphisms that alter ERAP activity, this study aimed instead to interrogate the expression effect of chromosome 5q15 polymorphisms to determine their effect on ERAP isoform and protein expression.
Methods. RNA sequencing and genotyping across chromosome 5q15 were performed to detect genetic variants in ERAP1 and ERAP2 associated with altered total gene and isoform-specific expression. The functional implication of a putative messenger RNA splice-altering variant on ERAP-1 protein levels was validated using mass spectrometry.
Results. Polymorphisms associated with ankylosing spondylitis (AS) significantly influenced the transcript and protein expression of ERAP-1 and ERAP-2. Disease risk-associated polymorphisms in and around both genes were also associated with increased gene expression. Furthermore, key risk-associated ERAP1 variants were associated with altered transcript splicing, leading to allele-dependent alternate expression of 2 distinct isoforms and significant differences in the type of ERAP-1 protein produced.
Conclusion. In accordance with studies demonstrating that polymorphisms that increase aminopeptidase activity predispose to immune disease, the increased risk also attributed to increased expression of ERAP1 and ERAP2 supports the notion of using aminopeptidase inhibition to treat AS and other ERAP-associated conditions. HLA-mediated presentation of endogenous peptides to CD8+ T cells educates the immune system to differentiate between self-derived and foreign antigens. Consequently, aberrations in peptide presentation pathways may evoke misinformed immune cell reactivity against host tissue, leading to pathology. Aminopeptidases function in the processing of peptide precursors to generate molecules of optimal length and composition for HLA loading. Disease risk-associated polymorphisms in the endoplasmic reticulum aminopeptidase genes ERAP1 and/ or ERAP2 are seen in several immune-mediated diseases, including ankylosing spondylitis (AS) (1, 2) , psoriasis (3), Crohn's disease (4) , and Behc ßet's disease (5) .
Robust genetic interactions exist between ERAP1 and the HLA class I alleles HLA-B27 and HLA-B40 in AS (1, 6) , HLA-Cw6 in psoriasis (3) , and HLA-B51 in Behc ßet's disease (5) . Synergism between HLA class I loci and ERAP1 is most pronounced in AS, with risk-associated polymorphisms in the gene contributing to strong disease risk (lead single-nucleotide polymorphism [SNP] rs30187; P = 4.4 9 10
À45
, odds ratio [OR] 1.29) (7) in HLA-B27 carriers alone (1) . Although 80-95% of AS patients carry the major genetic risk factor HLA-B27, this allele contributes only~20% of the genetic risk for the disease, and >113 additional genetic loci have confirmed disease associations (1, 2, (7) (8) (9) (10) . Evidence points to the involvement of altered peptide handling in disease pathogenesis (11) (12) (13) , potentially driving production of an immunogenic HLA-B27-specific peptide repertoire that misinforms the immune response and/or impedes the folding, stability, and function of HLA-B27.
In AS, the ERAP1 locus contains 2 independent association signals (1). The stronger is tagged by SNP rs30187 (K528R; OR 1.29, P = 4.4 9 10 À45 ) (7), the protective allele at which a~40% decrease in enzymatic activity is conferred (1) . Conversely, the rs30187 risk allele alters the HLA-B27-bound peptidome by causing both elevated production and destruction of different HLA-B27 epitopes (11, (14) (15) (16) . The second association signal is tagged by rs10050860 (D575N; P = 9.28 9 10
À36
). This SNP has previously been shown not to be functional in both recombinant protein and cellular assays (1, 17) , and the functional mechanism driving disease association at this signal has not been determined. In vitro studies have demonstrated that protective ERAP1 variants, as well as ERAP1 silencing or inhibition, reduce surface expression of HLA-B27 free heavy chains (18) , although this finding has not been universal (19) . HLA-B27 free heavy chain expression on the cell surface has been shown to induce the expansion of Th17 cells and secretion of the proinflammatory cytokine interleukin-17A (20) .
Homozygous deletion of ERAP1 in the HLA-B27-transgenic rat model of AS does not alter levels of folded HLA-B27 or HLA-B27 heavy-chain dimers on the surface of peripheral blood mononuclear cells (PBMCs) and does not prevent the development of spondyloarthritis (SpA) in these rats (21) . The relevance of this in human SpA is, however, unclear. Rats lack ERAP-2, which in humans is thought to interact with ERAP-1 to influence peptide presentation. Because the transgenic rats involved have at least 20 copies of the HLA-B27 transgene per cell, as opposed to 1 or 2 copies in human HLA-B27-positive AS, they may develop SpA as a result of a pathogenic process different from that in human disease. Evidence suggests that disease-associated polymorphisms in ERAP1 also exert an expression effect (12) , with the risk genotype being correlated with increased gene expression (22) .
At ERAP2, the AS-associated nonsense mutation rs2248374 is an expression quantitative trait locus (eQTL) at which the protective G allele results in complete loss of gene expression due to nonsense-mediated decay of an alternatively spliced transcript (23) . The presence of ERAP-2 influences the HLA-B27 peptide pool, decreasing the abundance of peptides with N-terminal basic residues and increasing the percentage of 9-mer peptides presented (24) , lowering the affinity of the HLA-B27 peptidome (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . Given the intricate role of both aminopeptidases in shaping the HLA-B27 peptidome, it is possible that variants increasing aminopeptidase expression may act concordantly to increase AS risk in individuals carrying disease-associated active variants of ERAP1 and ERAP2.
In the current study, we used RNA-Seq to identify ERAP1 and ERAP2 polymorphisms associated with varied gene and isoform expression in patients with AS and healthy controls. RNA-Seq allows interrogation of the transcriptional landscape of a gene, enabling identification of splice-altering variants (splicing QTLs [sQTLs] ) that may drive the production of distinct isoforms with phenotypic consequences. Despite extensive characterization of alternate ERAP2 transcripts that radically transform the global expression of this gene (23) , alternate isoforms of ERAP1 have been infrequently studied in the broader literature. We demonstrate that AS risk-associated single-nucleotide polymorphisms (SNPs) in ERAP1 and ERAP2 are associated with substantial eQTL effects at both the transcript and protein levels and show that risk-associated variants in ERAP1 are associated with altered splicing of the encoded gene transcript. This indicates that the disease-associated SNPs in ERAP1 and ERAP2 influence disease risk through effects on transcription and splice variation in addition to the functional effects of coding variants in ERAP1.
PATIENTS AND METHODS
Human research ethics. Human ethics approval was granted by Princess Alexandra Hospital and University of Queensland Ethics Committees (approval nos. Metro South HREC/05/QPAH/221 and UQ 2006000102). Written informed consent was received from all participants prior to inclusion in the study.
Sample selection. Fifty-four patients with AS diagnosed according to the modified New York criteria (26) and 70 healthy controls were included in this study. Peripheral venous blood was collected from AS patients at the Princess Alexandra Hospital Ankylosing Spondylitis Clinic, and PBMCs from patients and controls were collected as described previously (7) .
Genotyping, imputation, and disease association analysis. Genotyping was conducted during the 2013 Immunochip study of 9,049 AS patients and 13,607 healthy control subjects (7) . P values for SNP disease associations upon conditioning with rs30187 were derived using logistic regression on the complete Immunochip data set in Plink (http://pngu.mgh.harvard. edu/purcell/plink/ (27) , with inclusion of the rs30187 genotype as a covariate. Imputation of SNPs within an R 2 window value of 0.1 with rs30187 (ERAP1) or rs2910686 (ERAP2) was conducted using the 1000 Genomes phase 1 reference panel for the subset of 124 individuals included in this study. Phasing was conducted using SHAPEIT (28) , and imputation was conducted using IMPUTE2 (29) , with the "info" metric used to remove poorly imputed SNPs (info < 0.5). A total of 1,221 SNPs spanning ERAP1 and ERAP2 were used in the final analysis.
RNA sequencing. RNA was reverse transcribed, prepared for sequencing using an Illumina TruSeq Stranded Total RNA Library Prep Kit, and sequenced using an Illumina HiSeq 2000 system. Reads were mapped to the human genome Ensembl Genome Reference Consortium Build 37, release 75 (GRCh37.75) using TopHat version 2.0.6 employing the Bowtie 2 version 2.0.2 aligner (30, 31) . Aligned reads were supplied to HTSeq (32) to generate counts per gene. Isoform-specific reads were generated using the Cufflinks suite (33) and assembled into a reference transcriptome. RSEM (34) was used to align reads to generate isoform counts of known and novel transcripts. Gene and isoform counts were normalized using DESeq2 (35) .
Statistical analysis. Expression QTL detection. All statistical analyses were performed using R statistical software (36) . A generalized linear mixed-effects model (GLMM) with a negative binomial distribution and logarithmic link was fitted using the lme4 package (37) to test for the effect of genotype on gene or isoform expression, correcting for the fixed effect of patient sex and random effect of sequencing batch, according to the following equation:
family ¼ neg.binÞ
The change in gene or isoform expression attributed to the addition of a minor allele was quantified as the exponentiated regression coefficient for the genotype term (referred to here as the incidence rate ratio [IRR]), with IRR 2 interpretable as the fold change in expression in those homozygous for the minor allele relative to those homozygous for the major allele at a given SNP. P values were adjusted for multiple testing using Benjamini and Hochberg false discovery rate correction (38) .
Significant SNPs were cross-referenced to the set of significant disease-associated SNPs previously identified at this locus (7), and the direction of the effect of the disease risk allele was inferred. Pairwise conditioning was conducted by adding each significant eQTL individually as a covariate into the GLMM and assessing the genotype effect on expression at each remaining SNP, according to the following equation:
Wilcoxon's test was used to test for differences in gene expression between patients and controls.
Splicing QTL detection. Splicing QTLs were found for 2 highly expressed isoforms of ERAP1, herein termed isoform 19E and isoform 20E. The isoform 19E proportion for each individual was calculated from isoform counts as follows: isoform 19E/(isoform 19E + 20E). A 2-sample t-test was used to assess the difference in isoform proportion between patients and controls. A linear model was applied to test for the effect of genotype on isoform proportion while correcting for any disease status effect, according to the following equation: lmðisoform 19E proportion $ genotype þ statusÞ SNPs that were determined to be significant eQTLs for both transcripts, and significant sQTLs with an effect on isoform proportion, were cross-referenced to the set of significant disease-associated SNPs previously identified at this locus (7), and the direction of the effect of the disease risk allele was inferred. Wilcoxon's test was used to test for differences in isoform expression between patients and controls.
Haplotype data. A chi-square test was performed to assess the disease association of a haplotype containing the ERAP1 activity-altering SNP rs30187 and splice-altering SNP rs7063, using the European cohort of 9,069 AS patients and 13,578 healthy controls genotyped in the Immunochip investigation (7) .
Mass spectrometry (MS) for quantification of ERAP-1 isoform and total protein expression. PBMCs from 39 samples obtained from both patients and controls (15 homozygous for the risk [major] allele at rs7063; 15 heterozygous and 9 homozygous for the protective allele) (see Supplementary Samples were spiked with 0.5 fmoles weighted peptide mix standard for quantification, and 8 ll (~2 lg) was subjected to MS. A standard curve was generated by injecting 1 ll of peptide mix standards at 0.1 fmoles/ll, 0.2 fmoles/ll, 0.4 fmoles/ll, 0.6 fmoles/ll, and 0.8 fmoles/ll.
Statistical analysis of MS data. Mass chromatograms were analyzed using Skyline (39) to determine ERAP-1 isoform 19E, isoform 20E, and total protein concentrations in each sample. A linear model was used to test for the effect of the rs7063 genotype on protein expression for each isoform and total protein, correcting for the effect of disease status and HLA-B27 status. A t-test was used to test for differences in isoform or total ERAP-1 expression between patients and controls.
Protein modeling of ERAP-1 isoform 20E. The sequence of human ERAP-1 isoform 20E was obtained from UniProt sequence entry Q9NZ08-2. The sequence was submitted to the online modeling server Phyre2 (40) in intensive mode. A set of 4 templates was used by the server to generate the final model, with 92% of the sequence modeled at >90% confidence. A total of 80 residues (residues 1-45, 487-513, and 941-948) were built ab initio, including residues in the Cterminal extension caused by the additional exon 20.
Data access. The RNA sequencing data used for transcript expression analysis have been submitted to the NCBI Sequence Read Archive (project no. SRP100652, experiment no. SRX2586069), with all sample metadata included within BioProject (accession no. PRJNA376610).
RESULTS
Disease risk SNPs in ERAP1 and ERAP2 are associated with increased total gene expression. Total gene expression information (normalized transcript counts) was tested for an association with genotype at 1,221 genotyped and imputed SNPs across chromosome 5q15. There were 113 disease risk-associated SNPs identified as eQTLs significantly influencing total ERAP1 expression (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40369/abstract). At every SNP, the disease risk allele was associated with an increase in gene expression over the corresponding protective allele. Pairwise conditioning identified 38 SNPs as variants controlling the expression effect at this locus (see Supplementary Table 1) ; conditioning with any of these 38 SNPs abolished the significance of all 113 original eQTLs. The 38 variants span a region from the nineteenth intron of the gene to~50 kb upstream of the first exon ( Figure 1A ). All 38 SNPs lost their disease association but retained their expression association upon conditioning on rs30187, which itself displayed a modest eQTL effect (IRR 2 1.185, P = 2.4 9 10
À3
). Imputed SNP rs39840 (linked with genotyped SNPs rs27038 and rs27041; AS disease associations P = 5.7 9 10 À19 and P = 4.9 9 10 À19 , respectively) was the most significant eQTL Figure 1 . Correlation of genotypes across chromosome (Chr.) 5q15 locus single-nucleotide polymorphisms (SNPs) with endoplasmic reticulum aminopeptidase 1 (ERAP-1) and ERAP-2 gene expression. A and C, LocusZoom plots of P values for the effect of chromosome 5q15 locus SNPs on expression of ERAP1 (A) and ERAP2 (C) plotted against the genomic region. Expression quantitative trait loci (eQTLs) controlling for the expression effect are shown within the red brackets. Lead eQTLs are shown in purple. Boxed areas show SNPs colored according to linkage disequilibrium between these variants and according to the color key. B and D, Box plots of the lead ERAP1 eQTL rs39840 (risk allele G) genotype (B) and the lead representative ERAP2 SNP rs2927608 (risk allele A) genotype (D) versus total transcript expression of the corresponding gene. P values were derived from a generalized linear mixed-effects model testing for an effect of genotype on gene expression taken from normalized RNA sequencing counts. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th percentiles. Circles indicate outliers. In B, n = 79 in the CC genotype group, n = 39 in the CG group, and n = 6 in the GG group. In D, n = 44 in the GG genotype group, n = 54 in the GA group, and n = 26 in the AA group. identified (IRR 2 1.343, P = 1.5 9 10
À7
). Homozygosity for the risk allele at this SNP conferred a 34.3% increase in ERAP1 expression compared with the protective homozygous genotype (Figure 1B and Supplementary Table 1) . There was no significant difference in mean ERAP1 expression between AS patients and healthy controls.
ERAP2 expression has a bimodal distribution due to the effects of the rs2248374 nonsense mutation found at 50% frequency in the population (23) Figure 1C ) made it difficult to pinpoint a position for the eQTL signal. As at the ERAP1 locus, disease risk genotypes were consistently associated with increased gene expression at all expression-controlling SNPs within and around the ERAP-2 gene, with the risk genotype at the most significant eQTLs resulting in a 148% elevation in expression (IRR 2 2.476, P = 1.7 9 10 À6 ) ( Figure 1D ). There was no significant difference in mean ERAP2 expression between AS patients and healthy control subjects; this study had low power to detect such a difference given the small sample size (38 patients and 48 controls) upon removal of rs2248374 homozygotes and the need to control for rs2248374 (which is disease associated) in the analysis.
Alternate expression of 2 ERAP1 isoforms is governed by genotype and associated with disease. Eleven unique ERAP1 isoforms were assembled from RNA-Seq data (Supplementary Figure 1A, Figure 1B) . We identified 158 disease-associated SNPs as significant eQTLs for both isoforms when tested independently for an expression effect on each (see Supplementary Table 4 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40369/abstract). At every SNP, the disease risk variant was associated with a significant increase in expression of isoform 19E and a significant decrease in expression of isoform 20E. The proportion of isoform 19E transcripts expressed by an individual was significantly associated with disease status (P = 0.047 by t-test), with patients expressing a significantly greater proportion of the 19-exon isoform (66.1%) compared with controls (61.9%).
Genotyping of the same 158 disease-associated SNPs (henceforth called sQTLs) had significant effects on ERAP1 isoform proportions. Pairwise conditioning identified 9 SNPs that controlled for the sQTL effect; conditioning with any of these 9 SNPs ablated the effect of all other SNPs on the expression of isoform 20E and thus their effect on the isoform proportion (see Supplementary Table 4 ) of the 19-exon and 20-exon isoforms, respectively, than those homozygous for the protective allele ( Figures 3A and B) . Individuals heterozygous for rs7063 expressed similar amounts of both transcripts (for isoform 19E, 56%; for isoform 20E, 44%), whereas individuals homozygous for the risk allele expressed predominantly isoform 19E (average 71%), and those homozygous for the protective allele expressed predominantly isoform 20E (average 59%) ( Figure 3D) .
None of the 58 most significant sQTLs exhibited significant eQTL effects on total ERAP1 expression, and all retained a significant disease association upon correction for rs30187 (Supplementary Table 4 ) but lost this association upon correction for both rs30187 and rs10050860. These SNPs clustered within and around the C-terminus-encoding exons 19 and 20 ( Figure 3C ). Upon correction for rs10050860 alone, rs7063 retained a genome-wide significant disease association (P = 1.4 9 10
-10
). Conversely, a far weaker association remained for rs10050860 (P = 2.6 9 10 ) following correction for rs7063. LD between rs7063 and rs10050860 (R 2 = 0.55) was considerably stronger than that between rs7063 and rs30187 (R 2 = 0.21). A strong disease-protective haplotype results from co-occurrence of the protective alleles at rs30187 and the sQTL rs7063. The protective haplotype, rs30187C/ rs7063T (low ERAP1 enzyme activity/decreased expression of ERAP1 isoform 19E, increased expression of isoform 20E) showed a disease association of P = 1.1 9 10 -61 (Table 1) in 9,069 genotyped AS patients and 13,578 healthy controls. This haplotype association exceeded the individual disease association of both SNPs in isolation (for rs30187, P = 4.4 9 10 -45
; for rs7063, P = 1 .3 9 10
-41
). Genotype at ERAP1 sQTL rs7063 is strongly associated with alternate expression of 2 ERAP-1 isoforms at the protein level. Protein derived from both isoform 19E and isoform 20E of the ERAP1 transcript was detected using MS. The SNP genotype at rs7063 was significantly associated with protein expression of both isoforms independently and total ERAP-1 expression (the sum of the expression of both isoforms) ( Figures 3F and G) . Individuals homozygous for the risk allele at rs7063 expressed 3.52 times more isoform 19E (P = 3.1 9 10 -6 ) and 0.29 times less isoform 20E (P = 2.1 9 10 -5 ), and expressed 2.37 times more total ERAP-1 protein overall (P = 5.6 9 10 -5 ) than those homozygous for the protective allele. At the protein level, isoform 19E was the predominantly expressed form of ERAP-1 in all 3 genotype groups (Figure 3E) , and expression was significantly higher, on average, than expression of isoform 20E (P = 1.4 9 10 -10
). There was no significant difference in the mean expression of either isoform at the protein level, or total ERAP-1 protein levels, between AS patients and healthy controls.
In silico analysis of ERAP1 isoform 20E predicts folding nature of the alternate protein. Ab initio protein structure modeling of the ERAP-1 20E isoform suggested that the unique additional residues on the C-terminal end of the protein fold back across the surface of domain 4 of ERAP-1, potentially forming salt bridge interactions with residues Arg 750 and Arg 708 (Figure 4 ).
DISCUSSION
The genetic association of variants in ERAP1 and ERAP2 with several immune-mediated diseases makes these enzymes important targets for functional investigation. The current study shows that AS risk-associated variants in these genes consistently demonstrated an eQTL effect that increases aminopeptidase expression. Indeed, the protective influence of the nonsense mutation rs2248374 (23) in ERAP2 implies that some aspect of the functional role of the enzyme in peptide presentation is linked to pathology in a way that can be ablated with loss of expression. It is expected that this is also the case in ERAP1, at which increased expression may be exacerbating the pathogenic effect of co-occurring missense mutations shown to alter enzymatic activity and peptide handling (11, 12) . It has been previously shown that ERAP1 messenger RNA (mRNA) and protein expression is increased in lymphoid cell lines carrying disease susceptibility variants across ERAP1 haplotypes (15, 22) . Our results validate the influence of genetic variants across ERAP1 and ERAP2 on transcript and protein expression levels. Previous fine-mapping and haplotype evolution studies indicate that the ERAP1 association with AS is driven by 2 independent association signals, the first tagged by the coding variant rs30187 (K528R), which is likely the causative SNP, and the second tagged by the coding variant rs10050860 (D575N) (1,6) . Further studies using recombinant ERAP-1 and cell lines carrying ERAP-1 variants have shown that rs30187 has a substantial effect on peptide cleavage and peptides presented by HLA class I antigens (1, 17, 41) . It has been suggested that ERAP1 variants act in haplotype combinations (42, 43) . However, many of the variants and haplotypes observed in these studies have been found at frequencies that are markedly different from those reported in the literature and likely represent an experimental artifact (44, 45) . In the current study, we sought to investigate the functional mechanisms by which ERAP1 and ERAP2 variants operate, to explain the known genetic association of these genes with AS and other diseases.
The major finding of the current study suggests complex regulation of ERAP1 expression by 2 independently acting variants, 1 in moderate LD with rs30187, which influences global ERAP1 expression, and the second in moderate LD with rs10050860, which influences alternate splicing of 2 distinct transcripts. Our results suggest that the differences between these 2 forms of the ERAP1 transcript, and encoded protein, are critically important and influence the levels of functional enzymes in cells. Given the cross-disease-concordant action of ERAP1 and ERAP2 polymorphisms in conditions such as psoriasis and Crohn's disease (46) , these finding have relevance far beyond AS alone.
Harvey et al (12) demonstrated a strong positive correlation between the strength of AS disease association for variants in ERAP1 and their effect on ERAP1 expression (r = 0.75) (47) . Similarly, we observed that the most significant ERAP1 eQTLs are strongly associated with AS. Although linked within the haplotype containing the key functional variant rs30187, these SNPs retained a significant expression effect upon correction for rs30187. This implies that, in addition to the effects of rs30187 on ERAP-1 activity, there are ≥1 variants in moderate LD with rs30187 driving altered enzyme expression. Joint inheritance of these alleles would mean that any alterations in the HLA-B27 peptidome due to ERAP-1 hyperactivity would be exacerbated by enzyme overexpression. This could potentially flood HLA-B27 with an immunogenic repertoire stimulating the CD8-mediated immune response (48) or lead to destruction of peptides that protect (in some manner) against the immunologic processes that lead to AS (49) . Concordantly, increased transcript expression in individuals expressing ERAP2 and carrying ERAP2 disease risk-associated polymorphisms supports the significance of increased aminopeptidase expression in disease pathology. The identification of disease-associated expression-influencing variants at this locus, independent of the rs2248374-null mutant, implies that the patients who express ERAP-2 have varied expression phenotypes and thus disease susceptibility.
Of great interest was the finding that 2 expressed isoforms of ERAP1, the alternate expression of which correlated with genotype at strong disease risk-associated SNPs, may play a substantial role in disease. These 2 transcripts, encoding different versions of the ERAP-1 protein, have been previously identified (50, 51) and annotated as ENST00000443439 (19 exons, 18 coding; 19E) and ENST00000296754 (20 exons, 19 coding; 20E) in the Ensembl database (52) . Isoform quantification at the transcript level revealed that isoforms 19E and 20E are transcribed forms of ERAP1, expressed in all 124 individuals and at levels high enough to potentially contribute to the functional output of the enzyme.
We demonstrate here that alternate expression of these 2 isoforms is likely modulated by a genetic spliceinterfering variant rather than by the common mechanism of alternate splicing, and that this variant is strongly associated with AS. The observation that the disease riskassociated allele at all significant ERAP1 sQTLs correlated with increased expression of the 19E transcript and decreased expression of the 20E transcript suggests that there may be some disease-protective feature of the 20E isoform specifically. SNPs exhibiting the most significant sQTL effect were localized around the exon/intron 19 boundary, around the first point of sequence variation between the 2 isoforms, and it has been previously noted that a number of the strongest disease-associated variants 262 HANSON ET AL in ERAP1 fall in this location, with a potential involvement in splicing (12) . The most significant sQTLs retained a strong disease association upon correction for rs30187, implying that they are situated within the rs10050860-tagged haplotype; perhaps a splice site variant governing ERAP1 isoform expression is of greatest functional importance at this position. Our data suggest that the rs10050860 association is driven by the sQTL rs7063, but we cannot formally exclude effects due to other polymorphisms in strong LD with it, noting that rs10050860 itself has been shown not to affect ERAP-1 peptide cleavage (1, 17) .
MS quantification of isoform expression showed that both the 19E and 20E isoforms of the ERAP-1 protein were present at detectable levels in all 39 assayed samples. Similarly, observed differences in the molecular mass of ERAP-1 isolated from various human cell lines confirms the co-occurrence of the 2 forms of the fulllength protein (53) . One putative mRNA splice-altering mutation (rs7063) in ERAP1 contributed to marked variability in the type of ERAP-1 protein expressed. This variant has an association with AS of P = 1.3 9 10 -41 and an association of P = 2.5 9 10 -17 upon correction for rs30187. The observation that a far stronger association of rs7063 with AS remained after correction for rs10050860 (P = 1.4 9 10 -10 ) compared with the rs10050860 association upon correction for rs7063 (P = 2.6 9 10 -5 ) supports the notion that rs7063, or a marker in tight LD with it, is the more important variant at the second independent ERAP1 disease-associated haplotype.
SNP rs7063 falls in the middle of the conserved transcription termination sequence (AATAAA) in the 3ʹ-UTR of isoform 19E, a motif recognized by cleavage and polyadenylation-specific factors involved in 3ʹ-end transcription termination in mammals (54) . The risk allele (major allele T on the reverse strand in the motif AATAAA, allele A on the forward strand) would be expected to promote correct termination of the 19-exon form of the transcript, whereas the protective allele may result in loss of termination sequence recognition, producing the 20-exon form of the transcript. Variant rs111774449, falling in the splice donor sequence at the 3ʹ-end of exon 19 (55) , may also be a candidate for isoform switching but is rare (minor allele frequency of <0.01 in the ExAC data set) and was not genotyped or imputed in this study.
The strong disease-protective haplotype that arises from co-occurrence of rs30187 and rs7063 protective alleles is evidence that ERAP1 expression dynamics contribute to the pathogenicity afforded by increased enzyme activity. The enhanced genetic contribution of SNP haplotypes at 5q15 has been previously noted, with carriage of both disease-associated haplotypes increasing the risk by~4 fold, a far greater risk than the additive effects of either variant alone (1.2-1.3-fold for either variant in isolation) (1). The current study provides a potential functional mechanism to explain this observation.
Quantification of ERAP-1 protein isoforms in individuals with different rs7063 genotypes implied differences in the dynamics of translation from mRNA to protein. Despite approximately equal levels of the 19E and 20E transcripts in individuals heterozygous for rs7063, 81% of the ERAP-1 protein detected in these individuals was of the 19E isoform. This raises the question of whether loss of isoform 20E posttranscription due to sequence or structural variation between the 2 isoforms (gain of a C-terminal exon) perhaps contributes to less efficient translation of isoform 20E, or misfolding and degradation of the protein, with subsequent lack of function. If this is the case, the mechanism of protection conferred by the disease-protective genotype at splicesite SNPs may arise due to skewed expression toward the 20E transcript, subsequent loss of this isoform at the protein level, and thus a decrease in the overall level of functional ERAP-1 available to the cell.
Ab initio modeling of the additional amino acid residues of isoform 20E was required to explore the role of the exon 20 residues in the structure of ERAP-1. The area of ERAP-1 domain 4 with which the exon 20-derived residues are predicted to interact (Figure 4 ) is effectively invariant structurally between the open and closed forms of ERAP-1, implying that the presence of the isoform 20E C-terminal extension is unlikely to alter the open-to closed-form dynamics believed to be required for substrate binding and release (56, 57) . Tertiary structure modeling, however, could not predict whether these residues interfere with folding of the mature protein. The UCSC Genome Browser 100 vertebrate conservation track (58) shows very low sequence conservation in exon 20 relative to the other 19 exons of ERAP1 and, indeed, other coding exons in general. This suggests that 19-exon ERAP-1 is the predominant functional form of the enzyme, and that the appended 7 amino acids in isoform 20E are irrelevant to the mature enzyme, which is thus tolerant of substituting mutations, or that the protein itself is removed from the cell before it can actively contribute to peptide trimming.
To date, differential gene expression studies in AS have shown no evidence for significant changes in the expression of genes encoding disease-associated aminopeptidases in patients relative to healthy controls (59, 60) . Here, we demonstrate the ability of eQTL studies to identify genotype-driven altered gene expression in disease, which would go unnoticed by differential expression studies that pool samples of different genotypes. Importantly, it must be acknowledged that dynamic changes in the isoforms derived from a transcriptional unit can be far more insightful than measures of total gene expression, adding layers of complexity to the functional output of a gene. It appears that increased aminopeptidase expression governed by altered transcript dynamics at both ERAP1 and ERAP2 is a key mechanism driving the degree to which these enzymes contribute to immune-mediated disease. These findings support ERAP inhibition as a therapeutic approach to treating diseases including AS and psoriasis, in which protective genetic variants lead to loss of both ERAP levels and ERAP function.
